http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2004087125-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7559eb3109f5451d62562e7884cc5658 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dc924cf040545ff57fab39eb7b7b5557 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_88827fef39fcc54c84a2ad609bb65706 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_03b31edad1bbd555f8a7ee69e03f5fcc http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_89b83ecaaa26b4ba0857bf96a7ac8c90 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-705 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-705 |
| filingDate | 2004-04-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_29a4bc08e3e0cc2423d809e621059098 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a3743792acae353d0b54d126ee3b3517 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5ccc1e71d4d85faf077d9344b7305482 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fff48669f293012172992b9e7ba5e997 |
| publicationDate | 2004-10-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2004087125-A1 |
| titleOfInvention | Amino acid derivatives as inhibitors of mammalian sodium channels |
| abstract | Use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment or prevention of a condition selected from chronic and acute pain, tinnitus, bowel disorders, bladder dysfunctions and demyelinating diseases, Formula (I) wherein: - R1 is Cl-C6 alkyl, C6-C10 aryl, a 5- to 10- membered heteroaryl group, a 5- to 10- membered heterocyclyl group or a C3-C6 carbocyclyl group; each R2 is the same or different and represents Cl-C6 alkyl, halogen, Cl-C6 alkoxy, Cl-C6 alkythio, hydroxy, nitro, cyano, amino, (Cl-C6 alkyl)amino or di-( Cl-C6 alkyl)amino; - R3 represents hydrogen, Cl-C6 alkyl, or together with R4 represents a C2-C4 alkylene group; - R4 is hydrogen, Cl-C6 alkyl, C6-C10 aryl, C3-C6 carbocyclyl, a 5- to 10membered heteroaryl group, a 5- to 10- membered heterocyclyl group, -( Cl-C6 alkyl)-(C6-C10 aryl), -(C1-C6 alkyl)-(C3-C6 carbocyclyl), -(C1-C6 alkyl)-(5-to 10- membered heteroaryl), - ( Cl-C6 alkyl)-(5- to 10- membered heterocyclyl) or, together with R3 represents a C2-C4 alkylene group; - R5 and R6 are the same or different and each represent hydrogen or a Cl-C6 alkyl group; - n is 0,1, 2, 3 or 4; X1 represents a direct bond or a methylene group; and X2 represents a -CH2-, -CO-, -SO- or -S(O)2- group, wherein: the alkyl and alkylene groups and moieties in the substituents R1 to R6 and X, are unsubstituted or are substituted by 1, 2 or 3 substituents which are the same or different and are selected from hydroxy, amino, C1-C4 alkoxy, C1-C4 alkylthio, C1-C4 alkylamino and di(C1-C4 alkyl)amino substituents; and the aryl, heteroaryl, heterocyclyl and carbocyclyl groups and moieties in the substituents R1 and R4 are unsubstituted or are substituted by 1, 2 or 3 substituents which are the same or different and are selected from halogen, Cl-C6 alkyl, Cl-C6 alkoxy, Cl-C6 alkylthio, hydroxy, amino, Cl-C6 alkylamino, di-( Cl-C6 alkyl)amino, Cl-C6 haloalkyl, Cl-C6 haloalkoxy and Cl-C6 haloalkylthio substituents. provided that, when n is 1, 2, 3 or 4, R4 is other than hydrogen and when n is 0, X2 is -CH2- and R1 is an aryl or heteroaryl group, then either: (a) R, is a phenyl group which carries at least one -SCF3 substituent or is a thienyl group which carries at least one chloro substituent; (d) R1 is a phenyl group which carries at least one -CF3 substituent or at least two halogen substituents; or (e) R4 is benzyl or hydroxybenzyl and R1 is a phenyl group which carries a fluorine or -OCH3 substituent. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9051240-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8470877-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8519000-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8129427-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7855227-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2008151702-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EA-018195-B1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8916681-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2013000651-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9474737-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9474738-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9474739-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9585869-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9603832-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9248116-B2 |
| priorityDate | 2003-04-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1174.